Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
NCT03575065
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
88
Enrollment
INDUSTRY
Sponsor class
Conditions
HER2-negative Breast Cancer
Interventions
DRUG:
BGB-290
Sponsor
BeiGene